Cynata Therapeutics Ltd has released a press release.
March 2018 Quarterly Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Cynata Therapeutics Limited on 6ix
Story so far
Earlier from Cynata Therapeutics
- CYP Completes Patent Application related to CAR-T Therapy
- Further US Patent Granted for Cynata Cymerus Technology
- FDA Grants Orphan Drug Designation to Cyanta for CYP-001
- Excellent Data from Final Preliminary Evaluation Period
- Cynata Engineered MSC Study Review Reveals Promising Results
Later from Cynata Therapeutics
- Notice of Allowance from EPO for Patent Application
- Enrolment Completed in Cynatas Phase 1 Clinical Trial
- $5.2m placement of shares to Fidelity International
- Cynatas MSCs Effective in Model of Diabetic Wounds
- Positive 6-Month Data from Cohort 1 in Phase 1 Trial in GvHD
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics